Dermatitis News

SAN DIEGO — While it did not perform at the level of clinicians, ChatGPT could be used as a tool to improve patch testing efficiency for allergic contact dermatitis, according to a poster presentation here.

SAN DIEGO — Children with vs. without atopic dermatitis are more likely to experience learning and memory difficulties, according to a poster presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — Atopic dermatitis improvement was found with lebrikizumab treatment in patients with skin of color, according to interim study results presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — At the American Academy of Dermatology Annual Meeting, Galderma announced new data demonstrating nemolizumab’s long-term efficacy in treating prurigo nodularis and atopic dermatitis, according to a press release.

SAN DIEGO — In children aged 2 to 5 years with atopic dermatitis, roflumilast cream 0.05% significantly improved symptoms compared with vehicle, with improvement seen as early as 1 week after treatment, according to a speaker here.

SAN DIEGO — In this video perspective, Menas Kizoulis, senior director of global scientific engagement at Kenvue, discusses the company’s latest research presented at the American Academy of Dermatology Annual Meeting.

SAN DIEGO — New data showed Vtama cream achieved consistent and strong efficacy for the treatment of atopic dermatitis across all racial groups, according to a poster presentation at the 2024 American Academy of Dermatology Annual Meeting.

Despite blood eosinophils depletion, benralizumab did not show a clinical benefit over placebo in chronic spontaneous urticaria, according to a phase 2b trial.

WASHINGTON — The most effective treatments for atopic dermatitis may also be the most harmful, according to a study presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Arcutis has entered into a licensing agreement with Sato Pharmaceutical Co. Ltd. to develop, manufacture and commercialize topical roflumilast in Japan for the treatment of multiple skin conditions, according to a company press release.